Illinois
Phase 3 cancer trials in Illinois
139 Phase 3 cancer studies are recruiting participants at sites in 76 cities across Illinois as of November 18, 2026, according to ClinicalTrials.gov.
- No cost to ask
- Taking part is voluntary
- Studies are independently reviewed
Every Illinois city with a recruiting study
By research area: Lung Cancer (52), Breast Cancer (29), Prostate Cancer (22), Lymphoma (21), Pancreatic Cancer (8), Melanoma (7).
Chicago (94), Peoria (44), Decatur (42), O'Fallon (38), Springfield (35), Urbana (35), Effingham (31), Bloomington (28), Danville (28), Galesburg (28), Mattoon (28), Ottawa (28), Pekin (28), Peru (27), Washington (26), Canton (25), Carthage (25), Kewanee (25), Macomb (25), Princeton (25), Eureka (24), Glenview (24), Maywood (23), Orland Park (23), Warrenville (23), DeKalb (22), Geneva (22), Evanston (20), Park Ridge (20), Shiloh (20), Hinsdale (18), Oak Lawn (18), Lake Forest (17), Carterville (16), Grayslake (16), Libertyville (16), Oak Brook (16), Aurora (15), Crystal Lake (15), Downers Grove (15), Hazel Crest (15), Rockford (15), Barrington (14), Centralia (14), Dixon (14), Elgin (14), Mount Vernon (14), Naperville (14), New Lenox (14), Normal (14), Zion (14), Highland Park (13), Lisle (12), Elmhurst (10), Harvey (9), Alton (8), Arlington Heights (8), Niles (8), Oak Park (7), Plainfield (7), Carbondale (6), Moline (6), Palos Heights (6), Skokie (6), Burr Ridge (5), Homer Glen (5), Melrose Park (5), Chicago Ridge (3), Hines (3), Huntley (3), Winfield (3), McHenry (2), North Chicago (2), Quincy (2), Yorkville (2), Elk Grove (1).
The number after each city is how many studies have a recruiting site there. A study with sites in several cities is counted in each one.
Breast cancer: recently updated in Illinois
Basic details from each study's public record (the 12 most recently updated of 139). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Recruiting in
- Arlington Heights · Carterville · Skokie
- Registry record
- NCT06393374 · updated
Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Recruiting in
- Bloomington · Canton · Carterville · and 31 more U.S. locations
- Registry record
- NCT07391774 · updated
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Recruiting in
- Chicago
- Registry record
- NCT06841354 · updated
Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Illinois on ClinicalTrials.gov.
Lung cancer: recently updated in Illinois
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Recruiting in
- Chicago · DeKalb · Geneva · and 9 more U.S. locations
- Registry record
- NCT06498635 · updated
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Summit Therapeutics
- Recruiting in
- Carterville · Chicago · Evanston
- Registry record
- NCT06767514 · updated
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Daiichi Sankyo
- Recruiting in
- Hinsdale
- Registry record
- NCT06899126 · updated
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Boehringer Ingelheim
- Recruiting in
- Chicago · Lisle
- Registry record
- NCT07195695 · updated
Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Recruiting in
- Bloomington · Canton · Carthage · and 19 more U.S. locations
- Registry record
- NCT07388524 · updated
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Recruiting in
- Chicago
- Registry record
- NCT06422143 · updated
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Recruiting in
- Chicago · Hinsdale · Peoria
- Registry record
- NCT06623422 · updated
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Mirati Therapeutics Inc.
- Recruiting in
- Arlington Heights · Chicago · Springfield
- Registry record
- NCT06875310 · updated
Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Illinois on ClinicalTrials.gov.
Lymphoma: recently updated in Illinois
Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Recruiting in
- Chicago · Danville · Decatur · and 14 more U.S. locations
- Registry record
- NCT06337318 · updated
Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Illinois on ClinicalTrials.gov.
Ask about studies in Illinois
Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.
Before you contact a study
How taking part works
From your first question to your decision: what happens and who you talk to along the way.
Questions to ask a study team
What to ask about time, risks and your rights before you agree to anything.
Eligibility and screening
How a study team works out whether a study is suitable for you.
About these listings
These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 18, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that are in Phase 3, including combined Phase 2/3, as each study is coded in the registry.
Phase 3 Cancer Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.
Sources and further reading
- ClinicalTrials.gov study registry — ClinicalTrials.gov (National Library of Medicine)
- Terms and Conditions for use of ClinicalTrials.gov data — ClinicalTrials.gov (National Library of Medicine)
- Questions to Ask About Volunteering for a Research Study — HHS Office for Human Research Protections